Activated factor X inhibition ameliorates NF-κB-IL-6-mediated perivascular inflammation and pulmonary hypertension

2025/06/13 by Satomi Imakiire, Keiji Kimuro, Keimei Yoshida +16
Immunology and Microbiology · Medicine · #Blood Coagulation and Thrombosis Mechanisms #Cardiovascular, Neuropeptides, and Oxidative Stress Research #Macrophage Migration Inhibitory Factor

paper · doi:10.1152/ajplung.00303.2024

openalex publication_date 2025/06/13 · openalex created_date 2025/10/10 · openalex updated_date 2026/07/28

Abstract

This study demonstrated that chronic treatment with activated factor X (FXa) inhibitor ameliorated NF-κB-IL-6-mediated perivascular inflammation in a rat model with pulmonary arterial hypertension, which is associated with elevated FXa activity. FXa may act on pulmonary arterial smooth muscle cells, inducing cell proliferation and inflammatory response via upregulated PAR 1 , thereby contributing to pulmonary vascular remodeling. Understanding the patient-specific pathophysiology is a prerequisite for applying FXa-targeted therapy to the treatment of pulmonary arterial hypertension.

Related

• Inflammation and Immunity in the Pathogenesis of Pulmonary Arterial Hypertension
• Combined inhibition of FABP4/5 ameliorates pulmonary hypertension by reducing pulmonary vascular and right ventricular fibrosis
• Pulmonary Hypertension and Idiopathic Pulmonary Fibrosis
• Hypoxia-induced mitogenic factor (FIZZ1/RELMα) induces endothelial cell apoptosis and subsequent interleukin-4-dependent pulmonary hypertension
• LOXL2 inhibition ameliorates pulmonary artery remodeling in pulmonary hypertension